GLP-1 Receptor Agonists, Obesity, and PsA: 5 Things to Know
As the connection between obesity, psoriasis, and PsA grows clearer, so does the potential of GLP-1 RAs. Explore their emerging role at the intersection of metabolism and immune-mediated disease. Medscape Rheumatology
Gastroenterology Insights, Vol. 16, Pages 32: Leptin, Nesfatin-1, Glucagon-like Peptide 1, and Short-Chain Fatty Acids in Colon Cancer and Inflammatory Bowel Disease
Gastroenterology Insights, Vol. 16, Pages 32: Leptin, Nesfatin-1, Glucagon-like Peptide 1, and Short-Chain Fatty Acids in Colon Cancer and Inflammatory Bowel Disease Gastroenterology Insights doi: 10.3390/gastroent16030032 Authors: Tamás Ilyés Paul Grama Simona R. Gheorghe Vlad Anton Ciprian N. Silaghi Alexandra M. Crăciun Background: Short-chain fatty acids (SCFAs) are produced by the colon microbiome and bind […]
Why Obamacare Is About to Get a Lot More Expensive
People who buy health care on the Affordable Care Act (ACA) marketplace are about to be in for some sticker shock. Monthly out-of-pocket costs are set to jump as much as 75% for 2026 because of the disappearance of federal subsidies and higher rates from insurers. [time-brightcove not-tgx=”true”] “Most enrollees are going to be facing […]
Eli Lilly’s Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race
Key Points in This Article: Eli Lilly’s (LLY) Zepbound has outshone Novo Nordisk’s Wegovy, achieving superior weight-loss results in clinical trials. The weight-loss drug market is highly competitive, driven by the success of injectable GLP-1 drugs like Ozempic. An oral weight-loss pill is the industry’s ultimate goal, and Lilly’s latest announcement may have redefined the […]
GLP-1s can help address LGBTQ healthcare barriers: experts
Dana Piccoli tried everything to lose weight. She frequented the gym, went on and off diets and hired a personal trainer. When Piccoli decided to get on a GLP-1, it wasn’t a “short cut” to drop weight – it was a way for her to live her life comfortably. “When I told someone I was […]
Functional beverages evolve amid GLP-1 use and private label growth
As GLP-1 medications reshape eating habits and private label innovation booms, beverages must deliver nutrient density, low sugar and smart positioning to stay competitive, according to Ravi Jhala, VP of commercialization at FedUp Foods, a functional beverage manufacturer specializing in private label.
Genes, Vol. 16, Pages 1015: Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025
Genes, Vol. 16, Pages 1015: Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025 Genes doi: 10.3390/genes16091015 Authors: Lindsey G. Yoo Courtney L. Bordelon David Mendoza Jacqueline M. Stephens Obesity is an epidemic that currently impacts many nations. The persistence of this disease is shaped by both genetic and epigenetic factors that […]
Tasso, Inc. and SheMed Provide At-Home Blood Testing to UK Women for Personalized GLP-1 Treatments
SEATTLE & LONDON–(BUSINESS WIRE)–SheMed and Tasso partner to deliver at-home blood testing for safer, personalized GLP-1 treatments.
Pharmaceutics, Vol. 17, Pages 1115: Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro
Pharmaceutics, Vol. 17, Pages 1115: Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro Pharmaceutics doi: 10.3390/pharmaceutics17091115 Authors: Ioanna A. Anastasiou Anastasios Tentolouris Panagiotis Sarantis Athanasia Katsaouni Eleni Rebelos Iordanis Mourouzis Constantinos Pantos Nikolaos Tentolouris Background/Objectives: Glucagon-like peptide-1 (GLP-1) is an endogenous hormone with receptors widely expressed across multiple organs. GLP-1 receptor agonists […]
Treating heart failure patients with anti-obesity medication can reduce emissions and improve clinical outcomes
New research has found that the use of GLP-1 receptor agonists, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of health care and clinical outcomes when used to treat heart failure.